Dr. Falk Pharma Gmbh

Zedira Gmbh

Roland Greinwald

Rudolf Wilhelm

Markus Proels

Markus Pröls

Ralf Mohrbacher

Tanju Nacak

Bernhard Tewes

Ralf Pasternack

Wolfgang Mohr

Ralph Mueller

Rudolph Wilhelm

Markus Prols

Martin Hils

Peter Fickert

Ansgar Boegershausen

Michael Trauner

Ansgar Bögershausen

Ralph Müller

Disclosed is a storage-stable pharmaceutical formulation for rectal administration, containing budesonide or a pharmaceutically compatible salt or derivative thereof, and at least 80 wt % of a solid fat or a mixture of different solid fats, based on the total weight of the formulation, as well as at least one anti-oxidation agent that is compatible therewith.

Pharmaceutical formulation for the treatment of inflammatory changes to the rectum

The present invention relates to the use of Nor-UDCA in the treatment of hepatic steatosis in patients having a hepatic fat fraction of greater than 10%.

Use of nor-ursodeoxycholic acid for reducing liver fat

Disclosed is an optimized pharmaceutical formulation for the treatment of inflammatory conditions of the esophagus. A pharmaceutical formulation in the form of an orodispersible effervescent tablet is stable, easy to produce, and can be used without dissolving same in a liquid. It is not necessary to drink anything with the tablet as this would reduce the time that the budesonide solution remains in the affected regions of the esophagus. The effervescent tablet of the invention surprisingly resulted in an unexpectedly high rate of histological remission in patients with active eosinophilic esophagitis.

Optimized pharmaceutical formulation for the treatment of inflammatory conditions of the esophagus

An optimized pharmaceutical formulation for the treatment of inflammatory diseases of the colon is disclosed, wherein the pharmaceutical formulation is a capsule containing pellets, which capsule is suitable for oral administration and delivers the active substance in a targeted manner to the site of action, namely the colon. This is achieved by a complex and multiple coating of pellets, which permit a modified release of active substance. The release of the active substance is at its maximum only in the colon, with at the same time low blood plasma levels. The results of the pharmaceutical tests concerning in vitro release are corroborated by the results in pharmaco-kinetic and clinical studies and the clinical efficacy demonstrated by these. The formulation according to the invention has a very good medicinal safety.

Pellets having a multi-layer structure for delayed release of the active substance in the distal colon

The present invention relates to an oral enteric high-dose tablet comprising mesalazine as the active substance as well as its use.

Optimized high-dose mesalazine-containing tablet

Growing community of inventors

Kenzingen, Germany

Roland Greinwald